Czech Republic Petr Vaculík, country manager of PSI CRO, a privately owned Swiss clinical research organization (CRO), describes how the number of clinical trials is decreasing in the Czech Republic, although many continue to capitalize on the country’s universal healthcare system. Vaculík also shares his views on how to retain a strong…
Czech Republic Olga Starobová, medical director of Syneos Health Czech Republic, walks us through the steps put in place to ensure successful synergies during the merger between INC Research and InVentiv Health, which has created a unique company with both clinical and commercial operations under one roof. Starobová talks about her views…
Global With clinical trials having become extremely expensive to conduct, industry buzz around the potential of data and artificial intelligence (AI) to allay these costs has grown. However, experts are split as to the true potential of digital tools to reduce clinical development outlay and provide better patient outcomes in the…
China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…
Belgium Luxembourg Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home to the company’s Heist-op-den-Berg production facility, a key manufacturing site for the global group. Vanneste delivers a strong message about…
Europe EFPIA’s Nathalie Moll highlights how Europe can reverse its decline in the global medical research standings and once again make the continent a world leader in medical innovation. If the content of the Pharmaceutical Strategy undermines the ambition of the Industrial Strategy then there is a very real, immediate…
Global In an exclusive and wide-ranging interview, Tom O’Leary, chief information officer (CIO) of leading contract research organisation (CRO), ICON, highlights how data is already revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes. O’Leary also…
Czech Republic Pavla Rozmarová, clinical research associate manager & regional OD for the Czech affiliate of German CRO Scope International, describes how the Czech clinical research landscape has evolved in the past few years and how Scope has moved to employ a younger generation to capitalize on the industry’s technological shift. Moreover,…
Belgium Frank Swaelens, general manager of IQVIA in Belgium and Luxembourg, offers insights into the healthcare and life science ecosystem of Belgium and highlights the opportunities that exist for the country in innovation and digitalization. Swaelens goes on to describe the collaborative role that IQVIA can play as a human data…
China Bing Xu, GM of Vital River Laboratories, shares the company’s development in the last 20 years; the challenges of advantages of their JV with Charles River Laboratories; the importance of lab animals for the research & development of new drugs and therapies; their core capabilities and competitive advantage as the…
Belgium Françoise Smets, dean of the Faculty of Medicine and Dentistry at Université Catholique de Louvain (UCLouvain), introduces the innovation and research capacity of the institution as the top-ranking French-speaking university in Belgium. Smets goes on to give her assessment of the Belgian academic landscape and shares the importance of the…
Mexico Dr David Kershenobich Stalnikowitz, director-general of the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ) shares the many new initiatives the Institute has introduced in the past couple of years, the new focus on primary care provision in line with government priorities, and the ongoing construction of their…
See our Cookie Privacy Policy Here